Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T

GlobeNewswireApr 24 10:01 ET

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

Yahoo FinanceApr 15 09:55 ET

Forecasting The Future: 4 Analyst Projections For Cue Biopharma

Throughout the last three months, 4 analysts have evaluated Cue Biopharma (NASDAQ:CUE), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings,

BenzingaApr 9 10:01 ET

Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning

TipRanksApr 9 09:35 ET

Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel

Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel

Dow JonesApr 9 08:56 ET

Oppenheimer Maintains Outperform on Cue Biopharma, Maintains $10 Price Target

Oppenheimer analyst Leland Gershell maintains Cue Biopharma (NASDAQ:CUE) with a Outperform and maintains $10 price target.

BenzingaApr 9 08:22 ET